Clinical Trials · NCT00359879
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 377
- Start date
- Sep 2006
- Locations
- 15 sites, Brazil, Mexico
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12